1. Home
  2. AUDC vs ALXO Comparison

AUDC vs ALXO Comparison

Compare AUDC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioCodes Ltd.

AUDC

AudioCodes Ltd.

HOLD

Current Price

$8.88

Market Cap

267.0M

Sector

Utilities

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.79

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUDC
ALXO
Founded
1992
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.0M
240.8M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
AUDC
ALXO
Price
$8.88
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.50
$3.50
AVG Volume (30 Days)
77.1K
913.5K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
4.55%
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.24
N/A
Revenue Next Year
$2.18
N/A
P/E Ratio
$23.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.95
$0.41
52 Week High
$11.48
$2.66

Technical Indicators

Market Signals
Indicator
AUDC
ALXO
Relative Strength Index (RSI) 60.74 40.00
Support Level $8.78 $1.41
Resistance Level $9.19 $1.90
Average True Range (ATR) 0.24 0.16
MACD 0.02 -0.03
Stochastic Oscillator 58.17 29.37

Price Performance

Historical Comparison
AUDC
ALXO

About AUDC AudioCodes Ltd.

AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: